{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:44:34Z","timestamp":1779277474273,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.urolonc.2025.01.016","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:29:38Z","timestamp":1739996978000},"page":"318-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is primary retroperitoneal lymph node dissection the way forward for patients with testicular seminoma and limited retroperitoneal metastases?"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5595-3541","authenticated-orcid":false,"given":"Mithun","family":"Kailavasan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Power","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin B","family":"Beech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.urolonc.2025.01.016_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5489\/cuaj.7945","article-title":"Canadian Urological Association consensus guideline: management of testicular germ cell cancer","volume":"16","author":"Hamilton","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.016_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology Guidelines on Testicular Cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol"},{"issue":"37","key":"10.1016\/j.urolonc.2025.01.016_bib0003","doi-asserted-by":"crossref","first-page":"e12390","DOI":"10.1097\/MD.0000000000012390","article-title":"Recent global trends in testicular cancer incidence and mortality","volume":"97","author":"Park","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.urolonc.2025.01.016_bib0004","unstructured":"Canadian Cancer Society. Survival statistics for testicular cancer Available from: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/testicular\/prognosis-and-survival\/survival-statistics. accessed 8 January 2025."},{"key":"10.1016\/j.urolonc.2025.01.016_bib0005","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology - Testicular Cancer Version 1.2024 \u2014 March 15, 2024 2024 Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/testicular.pdf. accessed 8 January 2025."},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JCO.2014.56.2116","article-title":"Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance","volume":"33","author":"Kollmannsberger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.01.016_bib0007","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2002.07.062","article-title":"Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis","volume":"20","author":"Bokemeyer","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.016_bib0008","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1200\/JCO.2009.26.4655","article-title":"Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19\/EORTC 30982 study (ISRCTN27163214)","volume":"29","author":"Oliver","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0009","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clon.2011.09.005","article-title":"UK management practices in stage I seminoma and the Medical Research Council Trial of imaging and schedule in Seminoma Testis managed with surveillance","volume":"24","author":"Cafferty","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"10.1016\/j.urolonc.2025.01.016_bib0010","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s00345-022-04145-6","article-title":"Testicular germ cell tumours' clinical stage I: comparison of surveillance with adjuvant treatment strategies regarding recurrence rates and overall survival-a systematic review","volume":"40","author":"Ruf","year":"2022","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2022.12.010","article-title":"How much chemotherapy is required to optimise long-term outcomes in clinical stage 2 seminoma?","volume":"84","author":"Sigg","year":"2023","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.01.016_bib0012","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00345-021-03873-5","article-title":"Therapy of clinical stage IIA and IIB seminoma: a systematic review","volume":"40","author":"Heinzelbecker","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.016_bib0013","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdu447","article-title":"Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes","volume":"26","author":"Giannatempo","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.016_bib0014","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2004.01.020","article-title":"Stage II testicular seminoma: patterns of recurrence and outcome of treatment","volume":"45","author":"Chung","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.016_bib0015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO.2003.06.065","article-title":"Radiotherapy for stages IIA\/B testicular seminoma: final report of a prospective multicenter clinical trial","volume":"21","author":"Classen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.urolonc.2025.01.016_bib0016","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1200\/JCO.2006.10.5296","article-title":"Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer","volume":"25","author":"van den Belt-Dusebout","year":"2007","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.urolonc.2025.01.016_bib0017","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1200\/JCO.2008.18.5181","article-title":"Pulmonary function in long-term survivors of testicular cancer","volume":"27","author":"Haugnes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/bjc.2013.226","article-title":"Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumor survivors","volume":"109","author":"Willemse","year":"2013","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.016_bib0019","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1200\/JCO.2000.18.8.1725","article-title":"Cardiovascular morbidity in long-term survivors of metastatic testicular cancer","volume":"18","author":"Meinardi","year":"2000","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.016_bib0020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","article-title":"Cardiovascular disease as a long-term complication of treatment for testicular cancer","volume":"21","author":"Huddart","year":"2003","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.urolonc.2025.01.016_bib0021","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.016_bib0022","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/andr.12354","article-title":"Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome","volume":"5","author":"Bogefors","year":"2017","journal-title":"Andrology"},{"key":"10.1016\/j.urolonc.2025.01.016_bib0023","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8671832","article-title":"Toxicities associated with cisplatin-based chemotherapy and radiotherapy in long-term testicular cancer survivors","volume":"2018","author":"Fung","year":"2018","journal-title":"Adv Urol"},{"issue":"14","key":"10.1016\/j.urolonc.2025.01.016_bib0024","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jnci\/92.14.1165","article-title":"Treatment-associated leukemia following testicular cancer","volume":"92","author":"Travis","year":"2000","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1016\/j.urolonc.2025.01.016_bib0025","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/jnci\/dji278","article-title":"Second cancers among 40,576 testicular cancer patients: focus on long-term survivors","volume":"97","author":"Travis","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0026","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2010.03.041","article-title":"Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy","volume":"58","author":"Bryd\u00f8y","year":"2010","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.016_bib0027","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/cncr.11950","article-title":"Fertility after testicular cancer treatments: results of a large multicenter study","volume":"100","author":"Huyghe","year":"2004","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.urolonc.2025.01.016_bib0028","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2017.77.0735","article-title":"Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: a multi-institutional study","volume":"36","author":"Kerns","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.016_bib0029","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1200\/JCO.2004.05.205","article-title":"Mortality after cure of testicular seminoma","volume":"22","author":"Zagars","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.016_bib0030","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5489\/cuaj.8009","article-title":"Testicular cancer survivorship: long-term toxicity and management","volume":"16","author":"Shrem","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.016_bib0031","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2010.30.1044","article-title":"Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group","volume":"29","author":"Tandstad","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.016_bib0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.eururo.2022.04.031","article-title":"The GETUG SEMITEP trial: de-escalating chemotherapy in good-prognosis seminoma based on fluorodeoxyglucose positron emission tomography\/computed tomography","volume":"82","author":"Loriot","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.01.016_bib0033","doi-asserted-by":"crossref","unstructured":"Tabakin A., Sinae K., Polotti C., et al. Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma. 2019. accessed 8 January 2025.","DOI":"10.1200\/JCO.2019.37.7_suppl.534"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.016_bib0034","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.urolonc.2024.01.014","article-title":"Primary retroperitoneal lymph node dissection for clinical stage II seminoma: a systematic review and meta-analysis of safety and oncological effectiveness","volume":"42","author":"Kardoust Parizi","year":"2024","journal-title":"Urol Oncol"},{"issue":"16","key":"10.1016\/j.urolonc.2025.01.016_bib0035","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1200\/JCO.22.00624","article-title":"Surgery in early metastatic seminoma: a phase II trial of retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy","volume":"41","author":"Daneshmand","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0036","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.euo.2023.06.004","article-title":"Retroperitoneal lymph node dissection in clinical stage IIA\/B metastatic seminoma: results of the cologne trial of retroperitoneal lymphadenectomy In metastatic seminoma (COTRIMS)","volume":"7","author":"Heidenreich","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2022.10.021","article-title":"Phase 2 single-arm trial of primary retroperitoneal lymph node dissection in patients with seminomatous testicular germ cell tumors with clinical stage IIA\/B (PRIMETEST)","volume":"84","author":"Hiester","year":"2023","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.016_bib0038","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000003697","article-title":"Primary retroperitoneal lymph node dissection for seminoma metastatic to the retroperitoneum","volume":"211","author":"Matulewicz","year":"2024","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.urolonc.2025.01.016_bib0039","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.22.01822","article-title":"Primary retroperitoneal lymph node dissection for stage II seminoma: is surgery the new path forward?","volume":"41","author":"Tachibana","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.01.016_bib0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.05.006","article-title":"Primary retroperitoneal lymph node dissection as treatment for low-volume metastatic seminoma in a population-based cohort: the Swedish Norwegian Testicular Cancer Group experience","volume":"65","author":"Thor","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.016_bib0041","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.euo.2019.08.002","article-title":"Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumor: a population-based study from the Swedish Norwegian Testicular Cancer group","volume":"3","author":"Gerdtsson","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.016_bib0042","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/j.juro.2010.06.146","article-title":"Ejaculatory status and fertility rates after primary retroperitoneal lymph node dissection","volume":"184","author":"Beck","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.01.016_bib0044","article-title":"MP01-14 Retroperitoneal nodal distribution of metastatic seminoma: a clinical mapping study","author":"Zeng","year":"2024","journal-title":"J Urol"},{"issue":"32","key":"10.1016\/j.urolonc.2025.01.016_bib0045","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1200\/JCO.21.00637","article-title":"Testicular cancer in the cisplatin era: causes of death and mortality rates in a population-based cohort","volume":"39","author":"Hellesnes","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.016_bib0046","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.euf.2022.11.003","article-title":"Treatment outcomes for men with clinical stage II nonseminomatous germ cell tumors treated with primary retroperitoneal lymph node dissection: a systematic review","volume":"9","author":"Neuenschwander","year":"2023","journal-title":"Eur Urol Focus"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T16:02:59Z","timestamp":1746892979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1078143925000122"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is primary retroperitoneal lymph node dissection the way forward for patients with testicular seminoma and limited retroperitoneal metastases?","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}